Neuland Laboratories Limited

NSE NEULANDLAB.NS

Neuland Laboratories Limited Capital Expenditure for the year ending March 31, 2024: USD -17.22 M

Neuland Laboratories Limited Capital Expenditure is USD -17.22 M for the year ending March 31, 2024, a -114.08% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Neuland Laboratories Limited Capital Expenditure for the year ending March 31, 2023 was USD -8.05 M, a 36.28% change year over year.
  • Neuland Laboratories Limited Capital Expenditure for the year ending March 31, 2022 was USD -12.63 M, a 12.28% change year over year.
  • Neuland Laboratories Limited Capital Expenditure for the year ending March 31, 2021 was USD -14.39 M, a -122.29% change year over year.
  • Neuland Laboratories Limited Capital Expenditure for the year ending March 31, 2020 was USD -6.48 M, a 28.70% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
NSE: NEULANDLAB.NS

Neuland Laboratories Limited

CEO Mr. Davuluri Sucheth Rao
IPO Date Oct. 13, 2008
Location India
Headquarters Phoenix IVY Building
Employees 1,643
Sector Healthcare
Industries
Pharmaceuticals Chemicals & Advanced Materials Clinical Trials Drugstores & Retail Pharmacies Fertilizers
Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

StockViz Staff

February 12, 2025

Any question? Send us an email